Bempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk
DOI:
https://doi.org/10.12775/JEHS.2024.68.55416Keywords
bempedoic acid, dyslipidemia, cholesterolAbstract
Cardiovascular disease remains one of the leading causes of mortality worldwide, with elevated LDL cholesterol being a critical risk factor. Statins have long been the cornerstone of lipid-lowering therapy, but many patients fail to reach target LDL cholesterol levels due to statin intolerance or insufficient response, even when combined with ezetimibe. Recently, the lipid-lowering drug class has been expanded with the introduction of bempedoic acid, a novel agent that inhibits ATP-citrate lyase. Recent studies have demonstrated the efficacy and safety of bempedoic acid in reducing LDL cholesterol levels in patients with hypercholesterolemia, paving the way for its inclusion in clinical guidelines. This article provides a comprehensive overview of the latest evidence regarding bempedoic acid and its emerging role in lipid management.
Despite the widespread use of statins, many patients fail to achieve target LDL-C levels due to statin intolerance or insufficient response. This comprehensive review explores the emerging role of bempedoic acid, a novel lipid-lowering agent that inhibits ATP-citrate lyase, in the management of dyslipidemia and cardiovascular risk reduction.
Bempedoic acid, approved by the FDA in 2020, offers a unique mechanism of action that complements existing therapies. As a prodrug activated specifically in the liver, it avoids muscle-related side effects commonly associated with statins. Clinical trials have demonstrated its efficacy in reducing LDL-C levels, particularly in patients with statin intolerance or those requiring additional LDL-C lowering beyond maximally tolerated statin therapy.
The review synthesizes data from multiple phase 3 clinical trials, including CLEAR Wisdom and CLEAR Outcomes, which have shown significant LDL-C reductions with bempedoic acid monotherapy and in combination with other lipid-lowering agents. Notably, bempedoic acid not only lowers LDL-C but also reduces high-sensitivity C-reactive protein (hs-CRP) levels, suggesting potential anti-inflammatory effects.
Safety profiles from these trials indicate that bempedoic acid is generally well-tolerated, with minimal muscle-related adverse events. However, slight increases in serum creatinine and uric acid levels have been observed, warranting monitoring in certain patient populations.
Recent updates to clinical guidelines, including the 2024 European Society of Cardiology guidelines on coronary heart disease, now recommend bempedoic acid for specific patient groups. These include statin-intolerant patients not achieving LDL-C goals on ezetimibe alone, and those not reaching targets on maximum tolerated statin doses combined with ezetimibe.
This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with statin intolerance or requiring additional LDL-C reduction. As research continues, bempedoic acid's role in reducing cardiovascular events and its long-term safety profile will be further elucidated, potentially reshaping the landscape of dyslipidemia management and cardiovascular risk reduction.
References
Tummala, R. et al. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. Ann Med 54, 1287-1296 (2022). doi: 10.1080/07853890.2022.2059559.
Albosta, M., Grant, J. K. & Michos, E. D. Bempedoic acid: Lipid lowering for cardiovascular disease prevention. Heart Int 17, 27-34 (2023). doi: 10.17925/HI.2023.17.2.1.
Ballantyne, C. M. et al. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther 35, 853-864 (2021). doi: 10.1007/s10557-021-07147-5.
Ruscica, M. et al. Bempedoic Acid: for Whom and When. Curr Atheroscler Rep 24, 791-801 (2022). doi: 10.1007/s11883-022-01054-2.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: https://www.ncbi.nlm.nih.gov/books/NBK593301/ (2023).
Dron, J. S. & Hegele, R. A. Genetics of Lipid and Lipoprotein Disorders and Traits. Curr Genet Med Rep 4, 130-141 (2016). doi: 10.1007/s40142-016-0097-y.
Genest, J. Lipoprotein disorders and cardiovascular risk. J Inherit Metab Dis 26, 267-287 (2003). doi: 10.1023/a:1024449603891.
Bezsonov, E. E., Sobenin, I. A. & Orekhov, A. N. Lipids and Lipoproteins in Health and Disease. Biomedicines 10, 87 (2021). doi: 10.3390/biomedicines10010087.
Lamina, C. & Ward, N. C. Lipoprotein (a) and diabetes mellitus. Atherosclerosis 349, 63-71 (2022). doi: 10.1016/j.atherosclerosis.2022.04.016.
Stadler, J. T. & Marsche, G. Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function. Int J Mol Sci 21, 8985 (2020). doi: 10.3390/ijms21238985.
Hoogeveen, R. C. & Ballantyne, C. M. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem 67, 143-153 (2021). doi: 10.1093/clinchem/hvaa252.
Raulin, A. C. et al. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17, 72 (2022). doi: 10.1186/s13024-022-00574-4.
Mazzuferi, G. et al. High density lipoproteins and oxidative stress in breast cancer. Lipids Health Dis 20, 143 (2021). doi: 10.1186/s12944-021-01562-1.
Heeren, J. & Scheja, L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 50, 101238 (2021). doi: 10.1016/j.molmet.2021.101238.
Iqbal, Z. et al. Lipids and peripheral neuropathy. Curr Opin Lipidol 32, 249-257 (2021). doi: 10.1097/MOL.0000000000000770.
Yang, A. L. & McNabb-Baltar, J. Hypertriglyceridemia and acute pancreatitis. Pancreatology 20, 795-800 (2020). doi: 10.1016/j.pan.2020.06.005.
Holmes, M. V. et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol 71, 620-632 (2018). doi: 10.1016/j.jacc.2017.12.006.
Selvaggio, S. et al. Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio and monocyte-to-HDL cholesterol ratio as helpful biomarkers for patients hospitalized for deep vein thrombosis. Int J Mol Med 51, 52 (2023). doi: 10.3892/ijmm.2023.5255.
Feng, X. et al. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Prog Lipid Res 77, 101006 (2020). doi: 10.1016/j.plipres.2019.101006.
Ference, B. A. et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med 380, 1033-1042 (2019). doi: 10.1056/NEJMoa1806747.
Summary of Product Characteristics. Available at: https://ec.europa.eu/health/documents/community-register/2020/20200401147517/anx_147517_en.pdf (2024).
Pinkosky, S. L. et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 7, 13457 (2016). doi: 10.1038/ncomms13457.
Ballantyne, C. M. et al. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther 35, 853-864 (2021). doi: 10.1007/s10557-021-07147-5.
Bilen, O. & Ballantyne, C. M. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep 18, 61 (2016). doi: 10.1007/s11883-016-0611-4.
Lalwani, N. D. et al. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients. J Clin Lipidol 13, 568-579 (2019). doi: 10.1016/j.jacl.2019.05.003.
Masana Marín, L. & Plana Gil, N. Bempedoic acid: Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clin Investig Arterioscler 33 Suppl 1, 53-57 (2021). doi: 10.1016/j.arteri.2021.02.012.
Markham, A. Bempedoic Acid: First Approval. Drugs 80, 747-753 (2020). doi: 10.1007/s40265-020-01308-w.
Tomlinson, B., Chan, P., Zhang, Y. & Lam, C. W. K. Efficacy and safety of add-on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opin Pharmacother 21, 2137-2151 (2020). doi: 10.1080/14656566.2020.1801638.
Ray, K. K. et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 380, 1022-1032 (2019). doi: 10.1056/NEJMoa1803917.
Ballantyne, C. M. et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 27, 593-603 (2020). doi: 10.1177/2047487319864671.
Ballantyne, C. M. et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 277, 195-203 (2018). doi: 10.1016/j.atherosclerosis.2018.06.002.
Duell, P. B. et al. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials. J Clin Lipidol 18, e153-e165 (2024). doi: 10.1016/j.jacl.2023.12.005.
Rubino, J. et al. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial. J Clin Lipidol 15, 593-601 (2021). doi: 10.1016/j.jacl.2021.05.002.
Pirillo, A. & Catapano, A. L. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes 29, 161-166 (2022). doi: 10.1097/MED.0000000000000706.
Ballantyne, C. M. et al. Factors associated with enhanced low-density lipoprotein cholesterol lowering with bempedoic acid. J Am Heart Assoc 11, e024531 (2022). doi: 10.1161/JAHA.121.024531.
Mutschlechner, D. et al. Cardiovascular events in patients treated with bempedoic acid vs. placebo: Systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 9, 583-591 (2023). doi: 10.1093/ehjcvp/pvad052.
Ray, K. K. et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: Prespecified analysis of the CLEAR Outcomes randomized trial. Lancet Diabetes Endocrinol 12, 19-28 (2024). doi: 10.1016/S2213-8587(23)00316-9.
Bays, H. E. et al. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol 14, 649-659.e6 (2020). doi: 10.1016/j.jacl.2020.08.009.
Toth, P., Catapano, A., Helms, B. et al. Safety and efficacy of bempedoic acid in patients with renal impairment. JACC 79 Suppl 9, 1459 (2022). doi: 10.1016/S0735-1097(22)02450-0.
Stroes, E. S. G. et al. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. Atherosclerosis 373, 1-9 (2023). doi: 10.1016/j.atherosclerosis.2023.03.020.
Goldberg, A. C. et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom randomized clinical trial. JAMA 322, 1780-1788 (2019). doi: 10.1001/jama.2019.16585.
Nissen, S. E. et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388, 1353-1364 (2023). doi: 10.1056/NEJMoa2215024.
Mach, F. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 41, 111-188 (2020). doi: 10.1093/eurheartj/ehz455.
Vrints, C. et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J ehae177 (2024). doi: 10.1093/eurheartj/ehae177.
Virani, S. S. et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 148, e9-e119 (2023). doi: 10.1161/CIR.0000000000001168.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Łukasz Wołowiec, Małgorzata Pellowska, Michał Janiak, Lidia Wydeheft, Grzegorz Grześk, Walery Zukow
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 79
Number of citations: 0
